https://wiki.tiffa.net/w/index.php?action=history&feed=atom&title=Translations%3AInsulin_analog%2F5%2Fen 2026-08-18T08:07:47Z Revision history for this page on the wiki MediaWiki 1.43.0 https://wiki.tiffa.net/w/index.php?title=Translations:Insulin_analog/5/en&diff=130141&oldid=prev 2024-03-19T08:49:44Z

<p>Importing a new version from external source</p> <p><b>New page</b></p><div>===Aspart===<br /> {{main|Insulin aspart}}<br /> [[Novo Nordisk]] created &quot;aspart&quot; and marketed it as NovoLog/NovoRapid (UK-CAN) as a rapid-acting insulin analogue. It was created through [[recombinant DNA]] technology so that the amino acid, B28, which is normally [[proline]], is substituted with an [[aspartic acid]] residue. The sequence was inserted into the [[yeast]] genome, and the yeast expressed the insulin analogue, which was then harvested from a [[bioreactor]]. This analogue also prevents the formation of hexamers, to create a faster acting insulin. It is approved for use in CSII pumps and Flexpen, Novopen delivery devices for subcutaneous injection.<br /> ===Glulisine===<br /> {{main|Insulin glulisine}}<br /> Glulisine is rapid acting insulin analog from [[Sanofi-Aventis]], approved for use with a regular syringe, in an [[insulin pump]]. Standard syringe delivery is also an option. It is sold under the name Apidra. The FDA-approved label states that it differs from regular human insulin by its &#039;&#039;rapid onset and shorter duration of action&#039;&#039;.</div>

FuzzyBot